NCT00986336View on ClinicalTrials.gov

A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 28, 2001

Study Completion Date

November 30, 2002

Conditions
Bipolar Disorder
Interventions
DRUG

topiramate

1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)

DRUG

topiramate

2-100 mg tablets twice daily for 2 weeks (400 mg/day)

DRUG

risperidone

Twice daily, individualized dosing to stabilization at 1-6 mg/day.

DRUG

topiramate

2-25 mg tablets twice daily for 2 weeks (100 mg/day)

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00986336 - A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders | Biotech Hunter | Biotech Hunter